BRPI0712322A2 - compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos - Google Patents

compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos Download PDF

Info

Publication number
BRPI0712322A2
BRPI0712322A2 BRPI0712322-1A BRPI0712322A BRPI0712322A2 BR PI0712322 A2 BRPI0712322 A2 BR PI0712322A2 BR PI0712322 A BRPI0712322 A BR PI0712322A BR PI0712322 A2 BRPI0712322 A2 BR PI0712322A2
Authority
BR
Brazil
Prior art keywords
amyloid
compounds
methods
alzheimer
production
Prior art date
Application number
BRPI0712322-1A
Other languages
English (en)
Inventor
Daniel Paris
Michael J Mullan
Pancham Bakshi
Original Assignee
Roskamp Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roskamp Res Llc filed Critical Roskamp Res Llc
Publication of BRPI0712322A2 publication Critical patent/BRPI0712322A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSTOS E COMBINAçõES DESTES PARA A INIBIçãO DA PRODUçãO DE BETA-AMILóIDE E MéTODOS DE USO DOS MESMOS. São fornecidos compostos que podem ser usados em combinação para o tratamento de doenças associadas com uma condição associada com o acúmulo cerebral de amilóide de Alzheimer, como doença de Alzheimer. Também são fornecidos métodos de tratamento ou de redução do risco de desenvolvimento de produção de <225>-amilóide, depósito de <225> amilóide, neurotoxicidade de <225>-amilóide (incluindo hiperfosforilação anormal de tau) e microgliose associadas com acúmulo cerebral de amilóide de Alzheimer por administração de quantidades terapeuticamente eficazes de compostos que em combinação podem diminuir a produção de <225> amilóide e a capacidade de entrada de cálcio em células. Também são fornecidos métodos para o diagnóstico de doenças associadas com acúmulo cerebral de amilóide de Alzheimer em animais ou humanos por administração de quantidades diagnosticamenue eficazes dos compostos.
BRPI0712322-1A 2006-07-06 2007-07-06 compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos BRPI0712322A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81912906P 2006-07-06 2006-07-06
US60/819.129 2006-07-06
PCT/US2007/072959 WO2008006070A2 (en) 2006-07-06 2007-07-06 Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0712322A2 true BRPI0712322A2 (pt) 2012-02-22

Family

ID=38895495

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0712322-1A BRPI0712322A2 (pt) 2006-07-06 2007-07-06 compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos

Country Status (6)

Country Link
US (1) US20080058330A1 (pt)
KR (1) KR20090026275A (pt)
AU (1) AU2007269090A1 (pt)
BR (1) BRPI0712322A2 (pt)
CA (1) CA2655029A1 (pt)
WO (1) WO2008006070A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) * 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
WO2011134075A1 (en) * 2010-04-30 2011-11-03 The University Of Western Ontario Sox9 inhibitors
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
SI2560631T1 (sl) 2011-03-01 2014-06-30 Pharnext Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
CN103044316A (zh) * 2013-01-23 2013-04-17 石家庄学院 一种以咪唑离子液体为催化剂制备1,4-二氢吡啶的方法
US20150166476A1 (en) * 2013-12-17 2015-06-18 Yi-Cheng Chen Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta
JP6935883B2 (ja) * 2018-07-13 2021-09-15 五稜化薬株式会社 蛍光画像診断の前処理方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors

Also Published As

Publication number Publication date
US20080058330A1 (en) 2008-03-06
WO2008006070A3 (en) 2008-03-06
KR20090026275A (ko) 2009-03-12
AU2007269090A1 (en) 2008-01-10
CA2655029A1 (en) 2008-01-10
WO2008006070A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2008006070A3 (en) Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof
PH12014500239A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP3447491A3 (en) Diagnosis and treatments relating to th2 inhibition
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
BRPI0606690A2 (pt) composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
PH12012502079A1 (en) Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l&#39;obesite
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
WO2010080452A3 (en) siRNA COMPOUNDS AND METHODS OF USE THEREOF
MX2012006552A (es) Agentes de enlace amiloides.
BR112012028651A2 (pt) heterociclilbenzilpirazóis substituídos e uso do mesmo
DE602006014691D1 (de) DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
BR112014030325A2 (pt) composição farmacêutica para tratar ou prevenir doença neurodegenerativa e alimento funcional
CL2008003027A1 (es) Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades.
ZA202002103B (en) Compounds as mpges-1 inhibitors
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
BR112014014802A2 (pt) composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 4A E 5A ANUIDADES.